


VUmc Basispresentatie























































VUmc Basispresentatie







In sum

Most efficient ES-AFO is compromise between:

Increasing work done by the AFO
Decreasing ability to push-off

For clinical practice
An ES-AFO stiffness of 1.4 Nm deg-1 AFO is recommended in patients with reduced ankle push-off

Electromyographic biofeedback (EMG-BFB)

• Randomized Controlled Trial (Jonsdottir, Cattaneo et al.)

• 2 × 10 chronic **stroke** patients

- walk > 10 meter without aid

- manual muscle test grade 1-4

• 3D gait analysis at 0, 7 and 13 weeks

- comfortable walking speed, comfortable shoes


• Outcome measures


- Peak ankle power at push off

- Height normalized gait velocity (%h/s)

- Height normalized stride length (%h)

- Peak knee flexion in swing





VUmc Basispresentatie



In sum • EMG-BFB improves walking speed significantly and importantly (average 0.2 m/s increase) • Working mechanism (increased push-off → increased stride length → increased speed) supported • What was the active ingredient in the therapy? • But what does this mean for persons with MS?

